Study to Evaluate a Single Dose of LTX-109 in Subjects With COVID-19 (Coronavirus Disease 2019) Infection.

NCT ID: NCT04854928

Last Updated: 2021-09-20

Basic Information

• Recruitment Status: UNKNOWN
• Clinical Phase: PHASE2
• Total Enrollment: 60 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2021-05-03
• Study Completion Date: 2022-05-31

Brief Summary

A Phase IIa, double-blind, placebo-controlled, randomised study designed to evaluate the effect, safety and tolerability of LTX-109 administered topically to the anterior nares in subjects with COVID-19 infection.

Detailed Description

A total of 60 subjects will be randomised to achieve approximately 46 completed and evaluable subjects. Subjects will be randomised 1:1 to one single dose of either active treatment or placebo.

All potential study subjects will be contacted and invited to a screening video-call with the Investigator. Full verbal information will be given and the consent for participation in the study will be signed electronically.

Eligible subjects will be visited twice at home by a study nurse on Day 1. During the first visit, one standard deep nose swab (one nostril) and one from the anterior part of the nose (both nostrils) will be collected. Symptom score will be assessed by the subject before dosing. The investigational medicinal product (IMP) will then be applied topically to both nostrils by the study nurse.

The study nurse will come back to collect nasal swab samples 2 hours after administration of the IMP, using the same sampling procedure as for the baseline samples.

Subjects will use an electronic diary for daily registrations of adverse events, concomitant medications and symptom score until Day 7.

A follow-up phone contact will be performed 7 days after IMP administration.

Conditions

COVID-19

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: TRIPLE

Study Groups

LTX-109 treatment

Single Dose by Nasal application of LTX-109 gel 3%, 250 microliters in each nostril.

Group Type: EXPERIMENTAL

LTX-109 gel, 3%

Intervention Type: DRUG

A Single dose of LTX-109 gel will be applied topically to both nostrils by a qualified health professional. A large drop of IMP will be applied into each nostril and distributed to cover the whole area of the nostril.

Placebo

Single Dose by Nasal application of placebo gel, 250 microliters in each nostril.

Group Type: PLACEBO_COMPARATOR

Placebo gel

Intervention Type: DRUG

A Single dose of placebo gel will be applied topically to both nostrils by a qualified health professional. A large drop of IMP will be applied into each nostril and distributed to cover the whole area of the nostril.

Interventions

LTX-109 gel, 3%

A Single dose of LTX-109 gel will be applied topically to both nostrils by a qualified health professional. A large drop of IMP will be applied into each nostril and distributed to cover the whole area of the nostril.

Intervention Type: DRUG

Placebo gel

A Single dose of placebo gel will be applied topically to both nostrils by a qualified health professional. A large drop of IMP will be applied into each nostril and distributed to cover the whole area of the nostril.

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

1. Willing and able to give electronically signed informed consent for participation in the study.

2. Male or female subject ≥18 years of age at screening.

3. Women of child-bearing potential have to agree to use an acceptable birth control method during participation in the investigation and a negative pregnancy test (beta human chorionic gonadotropin dipstick test in urine) at Day 1 will be required.

4. A positive PCR test (polymerase chain reaction test) or antigen test for SARS-CoV-2. The positive result must be available no later than 4 days from initiation of symptoms, if any.

5. Duration of symptoms not exceeding 6 days prior to baseline/IMP administration (Day 1).

6. Access to a mobile phone or computer and ability to use the electronic diary application and to participate in web-based appointments.

Exclusion Criteria

1. History of any clinically significant disease or disorder which, in the opinion of the Investigator, may either put the subject at risk because of participation in the study, or influence the results or the subject's ability to participate in the study.

2. Other upper respiratory tract infection with concomitant symptoms that can influence the results, such as sinusitis or tonsillitis.

3. Known allergy or hypersensitivity to the components of the IMP.

4. Current use of immunosuppressive therapy within the last 4 weeks prior to Day 1 and during the study.

5. Current use of nasally administered drugs within the last 2 weeks prior to Day 1 and during the study.

6. Vaccinated against COVID-19 or scheduled for vaccination within the study period.

7. Previous COVID-19 infection.

8. Any systemic anti-viral treatment within the last 4 weeks prior to Day 1 and during the study.

9. Pregnant, nursing or actively trying to conceive a child.

10. Inability to take medications nasally.

11. In situ nasal jewellery or open nasal piercings.

12. Planned treatment or treatment with another investigational drug within 30 days prior to Day 1. Subjects consented and screened but not dosed in previous Phase I studies are not excluded.

13. Investigator considers the subject unlikely to comply with study procedures, restrictions and requirements.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

CTC Clinical Trial Consultants AB

INDUSTRY

Sponsor Role: collaborator

Pharma Holdings AS

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Christian Lütken, MD

Role: STUDY_DIRECTOR

Pharma Holdings AS

Locations

ClinSmart Sweden AB

Uppsala, , Sweden

Site Status: RECRUITING

Countries

Sweden

Central Contacts

Christian Lütken, MD

Role: CONTACT

Christian.lutken@pharmaholdings.no

+47 48 000 242

Johnny Ryvoll, MBA, B.Sc..

Role: CONTACT

ryvoll@pharmaholdings.no

+47 90 13 02 43

Other Identifiers

C21-109-09

Identifier Type: -

Identifier Source: org_study_id